Comparison of Protective Effects of Antidepressants Mediated by Serotonin Receptor in Aβ-Oligomer-Induced Neurotoxicity
Authors:
- Ken YamamotoKYKen Yamamoto
- Mayumi TsujiMTMayumi Tsuji
- Tatsunori OguchiTOTatsunori Oguchi
- Yutaro MommaYMYutaro Momma
- Hideaki OhashiHOHideaki Ohashi
- Naohito ItoNINaohito Ito
- Tetsuhito NoharaTNTetsuhito Nohara
- Tatsuya NakanishiTNTatsuya Nakanishi
- Atsushi IshidaAIAtsushi Ishida
- Masahiro HosonumaMHMasahiro Hosonuma
- Toru NishikawaTNToru Nishikawa
- Hidetomo MurakamiHMHidetomo Murakami
Open Access
- 23 May 2024
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 12 (6) , 1158
Abstract
Amyloid β-peptide (Aβ) synthesis and deposition are the primary factors underlying the pathophysiology of Alzheimer’s disease (AD). Aβ oligomer (Aβo) exerts its neurotoxic effects by inducing oxidative stress and lesions by adhering to cellular membranes. Though several antidepressants have been investigated as neuroprotective agents in AD, a detailed comparison of their neuroprotection against Aβo-induced neurotoxicity is lacking. Here, we aimed to elucidate the neuroprotective effects of clinically prescribed selective serotonin reuptake inhibitors, serotonin–norepinephrine reuptake inhibitors, and noradrenergic and specific serotonergic antidepressants at the cellular level and establish the underlying mechanisms for their potential clinical applications. Therefore, we compared the neuroprotective effects of three antidepressants, fluoxetine (Flx), duloxetine (Dlx), and mirtazapine (Mir), by their ability to prevent oxidative stress-induced cell damage, using SH-SY5Y cells, by evaluating cell viability, generation of reactive oxygen species (ROS) and mitochondrial ROS, and peroxidation of cell membrane phospholipids. These antidepressants exhibited potent antioxidant activity (Dlx > Mir > Flx) and improved cell viability. Furthermore, pretreatment with a 5-hydroxytryptamine 1A (5-HT1A) antagonist suppressed their effects, suggesting that the 5-HT1A receptor is involved in the antioxidant mechanism of the antidepressants’ neuroprotection. These findings suggest the beneficial effects of antidepressant treatment in AD through the prevention of Aβ-induced oxidative stress.Keywords
This publication has 52 references indexed in Scilit:
- Decreased 5‐HT1A binding in mild Alzheimer's disease—A positron emission tomography studySynapse, 2022
- Duloxetine-Induced Neural Cell Death and Promoted Neurite Outgrowth in N2a CellsNeurotoxicity Research, 2020
- Upregulation of antioxidant thioredoxin by antidepressants fluoxetine and venlafaxinePsychopharmacology, 2019
- Selective Serotonin Reuptake Inhibitors2019
- Fluoxetine delays the cognitive function decline and synaptic changes in a transgenic mouse model of early Alzheimer's diseaseJournal of Comparative Neurology, 2018
- Duloxetine Protects Human Neuroblastoma Cells from Oxidative Stress-Induced Cell Death Through Akt/Nrf-2/HO-1 PathwayNeurochemical Research, 2017
- What is the therapeutic value of antidepressants in dementia? A narrative reviewInternational Journal of Geriatric Psychiatry, 2016
- Late-Life Depression, Mild Cognitive Impairment, and DementiaJAMA Neurology, 2013
- Possible therapeutic implication of Aβ disturbances in depressionInternational Journal of Geriatric Psychiatry, 2007
- Amyloid deposition as the central event in the aetiology of Alzheimer's diseaseTrends in Pharmacological Sciences, 1991